Stock Ratings / Health Care / HELP / forecast

COLL (59) AVBP (29) ARDX (24) ANNX (30) ⌘ Pro Terminal →

Helus Pharma Inc. (HELP) 12-Month Stock Forecast & Price Target Cone

$10.71 -1.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.65

Helus Pharma Inc. (HELP) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $782.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HELP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HELP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Helus Pharma Inc. (NASDAQ: HELP) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $10.71 (-1.83% 1D, market cap $782.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, HELP ranks #244 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HELP compare to COLL and AVBP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HELP carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M) and AVBP (ArriVent BioPharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HELP?

▼

For Helus Pharma Inc. (HELP), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #244 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.65 (-0.52%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HELP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY HELP SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 0.5% FCF Margin ($21.9M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$11.03-3.1% Next Q

Q2 (-2Q)

Grade C$10.69-3.1% Next Q

Q3 (-1Q)

Grade C$10.36+3.4% Next Q

Current

Grade D+$10.71-0.7% Hist 90D α

Trajectory: C+ (62) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HELP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HELP currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.92) and Max Pain ($11.25) forces dealer call-delta covering toward $15.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HELP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HELP Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your HELP Position Size: $10,000

Shares at $10.71: 933.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $8.21

$7,666

$-2,334 (-23.3%)

12M Consensus BaseTarget $10.52

$9,823

$-177 (-1.8%)

12M Bull Case BreakoutTarget $15.91

$14,855

+$4,855 (+48.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$11	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$15	69%	B
JP MorganUS Large-Cap Research	SELL	$9	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HELP)

✓Walkthrough of HELP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HELP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +102.46%▼ DESCENDING CHANNEL

2026-11-02O $10.91H $10.91L $10.71C $10.71VOL 790.4K

RES: $11.99SUP: $9.56SMA50: $11.92SMA200: $7.73

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HELP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HELP Butterfly Map → + Track HELP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HELP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HELP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HELP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HELP)

Health Care Rank #244 of 1016 ⚔️ COLL vs HELP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HELP vs. COLL, AVBP, ARDX, ANNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Helus Pharma Inc. (HELP) ranks #244 by composite RQD confidence (54/100, grade D+) and #388 by equity capitalization ($782.5M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with HELP at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HELP ACTIVE Helus Pharma Inc.	D+	54/100	—	—	—	-1.83%	$782.5M	Benchmark Subject
COLL Collegium Pharmaceutical Inc.	C-	59/100	12.4x	59.3%	85.0%	+3.44%	$782.3M	/coll-vs-help →
AVBP ArriVent BioPharma Inc.	E	29/100	—	—	-35.0%	+1.40%	$786.5M	/avbp-vs-help →
ARDX Ardelyx Inc.	E	24/100	—	90.3%	-32.7%	0.00%	$772.5M	/ardx-vs-help →
ANNX Annexon Inc.	E	30/100	—	—	-35.0%	-0.74%	$760.2M	/annx-vs-help →

2. HELP Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Helus Pharma Inc. (HELP) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $782.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. HELP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HELP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HELP compare to COLL and AVBP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HELP?

Where is HELP trading relative to its 50-day, 200-day, and 52-week technical levels?

HELP last traded at $10.71 (-1.83% on volume of 790,395 shares), positioning the stock -10.15% below its 50-day simple moving average ($11.92) and +38.55% above its 200-day simple moving average ($7.73). Across its 52-week range of $3.76 to $15.15, HELP sits at the 61.0% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.37 to $12.05).

HELP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is HELP's 12-month stock price target?

Helus Pharma Inc. (HELP) carries a 12-month consensus base price target of $10.52 (-1.8% from $10.71), with a bull-case target of $15.91 and a bear-case floor of $8.21.

Is HELP stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates HELP D+ (Sell — SELL) with an RQD Confidence score of 54/100.

Direct Sub-Reports: HELP RQD Cockpit HELP 12M Forecast HELP Earnings & Move HELP Dividends & DRIP HELP Insiders & 13F HELP Whale Options HELP Profit Sankey HELP News & Why